Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
C-X-C motif chemokine ligand 9 (CXCL9), a candidate biomarker, reflects type 1 (T1) inflammation pathology. Here, we report the analytical performance and clinical characteristics of a new CXCL9 reagent for a fully automated immunoassay device. We evaluated the limits of blank, detection, and quantitation (LoQ) along with other efficacy parameters, and the ability of the assay to report patient health, COVID-19 status, and the presence of asthma and/or interstitial lung diseases (ILDs). The coefficient of variation for 5-day total precision using two instruments was 7% across two controls, serum, and plasma panels. LoQ of 2.2 pg/mL suggested the efficacy of the assay in detecting T1 inflammation in plasma or serum; no cross-reactivity or interference was observed. We identified high serum CXCL9 levels in samples from patients with acute COVID-19 infections (n = 57), chronic bird-related hypersensitivity pneumonitis (n = 61), asthma (n = 194), and ILDs (n = 84) compared to healthy individuals (< 39.0 pg/mL). Furthermore, CXCL9 levels increased with age in asthma patients, and an opposite trend was observed for T2 inflammatory factors. These results suggest the utility of the automated CXCL9 immunoassay for measuring CXCL9 in clinical samples and reflect its role in T1 inflammation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066986 | PMC |
| http://dx.doi.org/10.1038/s41598-023-32513-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The pTau217/Aβ plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease.
Drug Discov Ther
July 2025
Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
As the most prevalent form of dementia, Alzheimer's disease (AD) represents a major public health challenge. Early diagnosis is crucial to delaying disease progression, and yet the gold standard for detection of biomarkers - cerebral positron emission tomography (PET) imaging and cerebrospinal fluid biomarker analysis - is constrained by invasiveness, high costs, and limited accessibility. On May 16, 2025, the FDA granted its first clearance to the Lumipulse G blood test, which utilizes the plasma pTau217/Aβ ratio, for the diagnosis of amyloid plaques in symptomatic patients age 55 or older.
View Article and Find Full Text PDFPlasma biomarkers for early detection of alzheimer's disease: a cross-sectional study in a Japanese cohort.
Alzheimers Res Ther
June 2025
Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
Background: Plasma biomarkers offer a promising alternative to amyloid beta (Aβ) positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer's disease (AD). This cross-sectional study assessed the utility of multiple plasma biomarkers for diagnosing and staging AD in a Japanese cohort.
Methods: The assessed plasma biomarkers included Aβ42/40, phosphorylated tau (p-tau181 and p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), individually and in combination.
Diagnostic Value of Anti-HTLV-1-Antibody Quantification in Cerebrospinal Fluid for HTLV-1-Associated Myelopathy.
Viruses
October 2024
Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki 216-8512, Japan.
Article Synopsis
- The study investigates the effectiveness of testing cerebrospinal fluid (CSF) for anti-HTLV-1 antibodies in diagnosing HTLV-1-associated myelopathy (HAM), highlighting the diagnostic accuracy of various test kits.
- It found that while CSF antibody levels were stable when refrigerated, they were affected by freeze-thaw cycles, leading to strong correlations in test results across different methods used on samples from 92 patients (69 with HAM, 23 carriers).
- The results showed high diagnostic performance for HAM, with five test kits achieving 100% sensitivity and varying specificity, suggesting that these tests combined with clinical evaluation can improve HAM diagnosis.
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Front Immunol
February 2024
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Article Synopsis
- The study investigates the clinical significance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) in the context of cancer treatment effectiveness, specifically focusing on PD-1 blockade therapies.
- Researchers analyzed data from 171 patients with various advanced solid tumors who received treatments like nivolumab or pembrolizumab to understand the relationship between plasma levels of sPD-1 and sPD-L1 and patient outcomes.
- Results indicated that while sPD-1 and sPD-L1 levels alone weren't significantly linked to patient survival, a specific combination of low sPD-1 and high sPD-L1 was associated with poorer progression-free survival and a
Analytical Performance of a Novel Latex Turbidimetric Immunoassay, "Nanopia TARC", for TARC/CCL17 Measurement: A Retrospective Observational Study.
Diagnostics (Basel)
September 2023
Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Thymus- and activation-regulated chemokine (TARC, also known as CCL17) is used as a biomarker for atopic dermatitis. The methods currently used for its measurement are complex, time-consuming, and require large machinery, warranting the need for a method that is simple, has a quick turnaround time, and requires less complex machinery. We evaluated the analytical performance of a novel latex turbidimetric immunoassay method, "Nanopia TARC", on 174 residual serum samples from patients with skin or allergic diseases.
View Article and Find Full Text PDF